COMPASS Pathways Target of Unusually High Options Trading (NASDAQ:CMPS)

COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) was the target of some unusual options trading activity on Friday. Traders acquired 7,423 call options on the stock. This represents an increase of approximately 152% compared to the average volume of 2,940 call options.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the stock. Jefferies Financial Group Inc. bought a new stake in COMPASS Pathways in the third quarter valued at $7,890,000. Nantahala Capital Management LLC increased its position in COMPASS Pathways by 47.7% in the 2nd quarter. Nantahala Capital Management LLC now owns 4,179,930 shares of the company’s stock valued at $11,704,000 after acquiring an additional 1,350,698 shares during the period. Ameriprise Financial Inc. bought a new stake in COMPASS Pathways during the 3rd quarter valued at $6,926,000. Hsbc Holdings PLC bought a new position in shares of COMPASS Pathways in the second quarter worth $3,011,000. Finally, Two Sigma Investments LP raised its stake in shares of COMPASS Pathways by 838.4% during the third quarter. Two Sigma Investments LP now owns 1,075,277 shares of the company’s stock valued at $6,161,000 after purchasing an additional 960,685 shares in the last quarter. 46.19% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on CMPS. Morgan Stanley raised their price target on shares of COMPASS Pathways from $10.00 to $11.00 and gave the company an “overweight” rating in a report on Wednesday, November 5th. BTIG Research upped their price objective on shares of COMPASS Pathways from $7.00 to $14.00 and gave the company a “buy” rating in a research report on Monday, October 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of COMPASS Pathways in a research report on Wednesday. Finally, Royal Bank Of Canada increased their price target on COMPASS Pathways from $16.00 to $21.00 and gave the company an “outperform” rating in a report on Friday. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $16.25.

COMPASS Pathways Stock Performance

Shares of NASDAQ:CMPS traded up $0.27 on Friday, reaching $7.40. 1,115,718 shares of the company’s stock were exchanged, compared to its average volume of 1,547,970. The business’s 50-day moving average is $6.38 and its two-hundred day moving average is $5.55. The company has a quick ratio of 1.23, a current ratio of 1.23 and a debt-to-equity ratio of 0.55. COMPASS Pathways has a fifty-two week low of $2.25 and a fifty-two week high of $8.20. The firm has a market capitalization of $710.36 million, a price-to-earnings ratio of -2.72 and a beta of 1.92.

COMPASS Pathways (NASDAQ:CMPS) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.38) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.02. As a group, equities research analysts forecast that COMPASS Pathways will post -2.33 EPS for the current year.

About COMPASS Pathways

COMPASS Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, COMPASS Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.